Download
13293_2024_Article_647.pdf 4,93MB
WeightNameValue
1000 Titel
  • Sex-specific molecular signature of mouse podocytes in homeostasis and in response to pharmacological challenge with rapamycin
1000 Autor/in
  1. Al-Diab, Ola |
  2. Sünkel, Christin |
  3. Blanc, Eric |
  4. Catar, Rusan Ali |
  5. Ashraf, Muhammad Imtiaz |
  6. Zhao, Hongfan |
  7. Wang, Pinchao |
  8. Rinschen, Markus M. |
  9. Fritsche-Guenther, Raphaela |
  10. Grahammer, Florian |
  11. Bachmann, Sebastian |
  12. Beule, Dieter |
  13. Kirwan, Jennifer A. |
  14. Rajewsky, Nikolaus |
  15. Huber, Tobias B. |
  16. Gürgen, Dennis |
  17. Kusch, Angelika |
1000 Verlag BioMed Central
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-09-15
1000 Erschienen in
1000 Quellenangabe
  • 15(1):72
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s13293-024-00647-7 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11404044/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Sex differences exist in the prevalence and progression of major glomerular diseases. Podocytes are the essential cell-type in the kidney which maintain the physiological blood-urine barrier, and pathological changes in podocyte homeostasis are critical accelerators of impairment of kidney function. However, sex-specific molecular signatures of podocytes under physiological and stress conditions remain unknown. This work aimed at identifying sexual dimorphic molecular signatures of podocytes under physiological condition and pharmacologically challenged homeostasis with mechanistic target of rapamycin (mTOR) inhibition. mTOR is a crucial regulator involved in a variety of physiological and pathological stress responses in the kidney and inhibition of this pathway may therefore serve as a general stress challenger to get fundamental insights into sex differences in podocytes.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>The genomic ROSAmT/mG-NPHS2 Cre mouse model was used which allows obtaining highly pure podocyte fractions for cell-specific molecular analyses, and vehicle or pharmacologic treatment with the mTOR inhibitor rapamycin was performed for 3 weeks. Subsequently, deep RNA sequencing and proteomics were performed of the isolated podocytes to identify intrinsic sex differences. Studies were supplemented with metabolomics from kidney cortex tissues.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Although kidney function and morphology remained normal in all experimental groups, RNA sequencing, proteomics and metabolomics revealed strong intrinsic sex differences in the expression levels of mitochondrial, translation and structural transcripts, protein abundances and regulation of metabolic pathways. Interestingly, rapamycin abolished prominent sex-specific clustering of podocyte gene expression and induced major changes only in male transcriptome. Several sex-biased transcription factors could be identified as possible upstream regulators of these sexually dimorphic responses. Concordant to transcriptomics, metabolomic changes were more prominent in males. Remarkably, high number of previously reported kidney disease genes showed intrinsic sexual dimorphism and/or different response patterns towards mTOR inhibition.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Our results highlight remarkable intrinsic sex-differences and sex-specific response patterns towards pharmacological challenged podocyte homeostasis which might fundamentally contribute to sex differences in kidney disease susceptibilities and progression. This work provides rationale and an in-depth database for novel targets to be tested in specific kidney disease models to advance with sex-specific treatment strategies.</jats:p></jats:sec>
1000 Sacherschließung
lokal Female [MeSH]
lokal MTOR Inhibitors/pharmacology [MeSH]
lokal Homeostasis/drug effects [MeSH]
lokal Proteome
lokal Sirolimus/pharmacology [MeSH]
lokal Animals [MeSH]
lokal Sex differences
lokal Mice [MeSH]
lokal Male [MeSH]
lokal Metabolome
lokal Transcriptome
lokal Podocytes/drug effects [MeSH]
lokal Research
lokal Transcriptome [MeSH]
lokal mTOR
lokal Podocytes
lokal TOR Serine-Threonine Kinases/metabolism [MeSH]
lokal Sex Characteristics [MeSH]
lokal Podocytes/metabolism [MeSH]
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/QWwtRGlhYiwgT2xh|https://frl.publisso.de/adhoc/uri/U8O8bmtlbCwgQ2hyaXN0aW4=|https://frl.publisso.de/adhoc/uri/QmxhbmMsIEVyaWM=|https://frl.publisso.de/adhoc/uri/Q2F0YXIsIFJ1c2FuIEFsaQ==|https://frl.publisso.de/adhoc/uri/QXNocmFmLCBNdWhhbW1hZCBJbXRpYXo=|https://frl.publisso.de/adhoc/uri/WmhhbywgSG9uZ2Zhbg==|https://frl.publisso.de/adhoc/uri/V2FuZywgUGluY2hhbw==|https://frl.publisso.de/adhoc/uri/Umluc2NoZW4sIE1hcmt1cyBNLg==|https://frl.publisso.de/adhoc/uri/RnJpdHNjaGUtR3VlbnRoZXIsIFJhcGhhZWxh|https://frl.publisso.de/adhoc/uri/R3JhaGFtbWVyLCBGbG9yaWFu|https://frl.publisso.de/adhoc/uri/QmFjaG1hbm4sIFNlYmFzdGlhbg==|https://frl.publisso.de/adhoc/uri/QmV1bGUsIERpZXRlcg==|https://frl.publisso.de/adhoc/uri/S2lyd2FuLCBKZW5uaWZlciBBLg==|https://frl.publisso.de/adhoc/uri/UmFqZXdza3ksIE5pa29sYXVz|https://frl.publisso.de/adhoc/uri/SHViZXIsIFRvYmlhcyBCLg==|https://frl.publisso.de/adhoc/uri/R8O8cmdlbiwgRGVubmlz|https://frl.publisso.de/adhoc/uri/S3VzY2gsIEFuZ2VsaWth
1000 Hinweis
  • DeepGreen-ID: 112ecf519c124909bc432279774c3cdf ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search) ; at least one of the mandatory fields 'given-names' and 'family-name' is missing for the ORCID profile of 'Kusch, Angelika' (https://orcid.org/0000-0002-6666-7081)
1000 Label
1000 Förderer
  1. Pfizer Pharma GmbH |
  2. Deutscher Akademischer Austauschdienst |
  3. Deutsche Forschungsgemeinschaft |
  4. Novo Nordisk Fonden |
  5. Aarhus Universitets Forskningsfond |
  6. Charité – Universitätsmedizin Berlin |
1000 Fördernummer
  1. -
  2. -
  3. -
  4. -
  5. -
  6. -
1000 Förderprogramm
  1. -
  2. -
  3. -
  4. -
  5. -
  6. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Pfizer Pharma GmbH |
    1000 Förderprogramm -
    1000 Fördernummer -
  2. 1000 joinedFunding-child
    1000 Förderer Deutscher Akademischer Austauschdienst |
    1000 Förderprogramm -
    1000 Fördernummer -
  3. 1000 joinedFunding-child
    1000 Förderer Deutsche Forschungsgemeinschaft |
    1000 Förderprogramm -
    1000 Fördernummer -
  4. 1000 joinedFunding-child
    1000 Förderer Novo Nordisk Fonden |
    1000 Förderprogramm -
    1000 Fördernummer -
  5. 1000 joinedFunding-child
    1000 Förderer Aarhus Universitets Forskningsfond |
    1000 Förderprogramm -
    1000 Fördernummer -
  6. 1000 joinedFunding-child
    1000 Förderer Charité – Universitätsmedizin Berlin |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6521167.rdf
1000 Erstellt am 2025-07-06T05:59:41.496+0200
1000 Erstellt von 322
1000 beschreibt frl:6521167
1000 Zuletzt bearbeitet 2025-08-04T09:35:44.741+0200
1000 Objekt bearb. Mon Aug 04 09:35:44 CEST 2025
1000 Vgl. frl:6521167
1000 Oai Id
  1. oai:frl.publisso.de:frl:6521167 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source